Quadrivalent Human Papillomavirus Vaccine (4vHPV, GARDASIL®) actually Fails in protecting Men who Have Anal Sex, transgender (wanna be women MEN), gay men etc.; devastating results! PSAs are needed!

by Paul Alexander

McCullough comes out swinging & I stand by his interpretation as I look at the data & methods carefully! this study showed the 4vHPV, GARDASIL fails; MSM, trans etc. need strong public health messages



‘Among 666 participants, 400 (60.1%) had any anal HPV, and 146 (21.9%) had a 4vHPV type. Among vaccinated participants, 18, 36, and 177 reported exclusively insertive, exclusively receptive, or both sexual positioning practices, respectively. Compared with participants reporting exclusively insertive anal sex, odds of any HPV were significantly higher among participants engaging exclusively in receptive anal sex (adjusted odds ratio [aOR], 5.90; 95% confidence interval [CI], 2.52-13.78), as well as those engaging in both (aOR, 3.32; 95% CI, 1.71-6.44). Vaccinated participants, compared with unvaccinated participants, had lower odds of 4vHPV-type HPV regardless of sexual positioning practices (aOR, 0.56; 95% CI, 0.34-0.92).’

But a 44% reduction in risk is a failure with this vaccine.

McCullough is correct in that ‘These data suggest public health efforts would be better spent on this high risk population rather than a one-size-fits-all blanket vaccination strategy for lower risk groups.’

See McCullough’s excellent substack below:

Courageous Discourse™ with Dr. Peter McCullough & John Leake
Quadrivalent Human Papillomavirus Vaccine (4vHPV, GARDASIL®) Fails to Protect Men who Have Anal Sex
By Peter A. McCullough, MD, MPH The quadrivalent human papillomavirus vaccine 4vHPV, GARDASIL® was approved in the US in 2009 for use in males aged 9 to 26 for the prevention of HPV-related genital warts, and in 2010 for the prevention of certain HPV-related anogenital diseases. It is widely used in normal boys and girls who are at low risk for serious …
Read more